Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 17/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 17/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 17/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 17/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 17/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720088 | 0.76 | PIN1 (0.52) | MEN1KMT2A | |
| SCHEMBL9831234 | 0.75 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL30472756 | 0.74 | LTA4H (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL30472758 | 0.74 | LTA4H (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29037096 | 0.73 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2115724 | 0.73 | ALDH1A1 (0.51) | MEN1KMT2A | |
| SCHEMBL4003083 | 0.73 | GRIN1 (0.51) | — | |
| SCHEMBL5897623 | 0.72 | MEN1 (0.48) | MEN1KMT2A | |
| SCHEMBL6369816 | 0.71 | SLC6A2 (0.46) | KMT2A | |
| SCHEMBL19417331 | 0.70 | MAPT (0.52) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268280-B1 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8173672-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173672-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009117283-A2 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046145-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | CHRM2 2/4885CHRM4 4/4885CHRM5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.